Comparative assessment of clinical benefit using the ESMO-magnitude of clinical benefit scale version 1.1 and the ASCO value framework net health benefit score NI Cherny, EGE De Vries, U Dafni, E Garrett-Mayer, SE McKernin, ... Journal of Clinical Oncology 37 (4), 336-349, 2019 | 111 | 2019 |
Evaluation of NGS and RT-PCR methods for ALK rearrangement in European NSCLC patients: results from the European Thoracic Oncology Platform Lungscape Project I Letovanec, S Finn, P Zygoura, P Smyth, A Soltermann, L Bubendorf, ... Journal of Thoracic Oncology 13 (3), 413-425, 2018 | 77 | 2018 |
Gender-related challenges facing oncologists: the results of the ESMO Women for Oncology Committee survey S Banerjee, U Dafni, T Allen, D Arnold, G Curigliano, E Garralda, ... ESMO open 3 (6), e000422, 2018 | 71 | 2018 |
A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M … RA Soo, JY Han, U Dafni, BC Cho, CM Yeo, E Nadal, E Carcereny, ... Annals of Oncology 33 (2), 181-192, 2022 | 59 | 2022 |
Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy–results from the randomised phase II ETOP/IFCT 4-12 … S Peters, JL Pujol, U Dafni, M Dómine, S Popat, M Reck, J Andrade, ... Annals of Oncology 33 (1), 67-79, 2022 | 56 | 2022 |
Report on the status of women occupying leadership roles in oncology E Hofstädter-Thalmann, U Dafni, T Allen, D Arnold, S Banerjee, ... ESMO open 3 (6), e000423, 2018 | 45 | 2018 |
Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring B Gyawali, EGE De Vries, U Dafni, T Amaral, J Barriuso, J Bogaerts, ... ESMO open 6 (3), 100117, 2021 | 44 | 2021 |
Proton pump inhibitors negatively impact survival of PD-1 inhibitor based therapies in metastatic melanoma patients K Homicsko, G Richtig, F Tuchmann, Z Tsourti, D Hanahan, G Coukos, ... Annals of Oncology 29, x40, 2018 | 37 | 2018 |
EHA evaluation of the ESMO—Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1. 1) for haematological malignancies B Kiesewetter, NI Cherny, N Boissel, F Cerisoli, U Dafni, EGE De Vries, ... ESMO open 5 (1), e000611, 2020 | 14 | 2020 |
Off-label despite high-level evidence: a clinical practice review of commonly used off-patent cancer medicines G Zarkavelis, AL Amylidi, C Verbaanderd, NI Cherny, Y Metaxas, ... ESMO open 8 (1), 100604, 2023 | 8 | 2023 |
Lessons learnt from scoring adjuvant colon cancer trials and meta-analyses using the ESMO-Magnitude of Clinical Benefit Scale V. 1.1 DG Knapen, NI Cherny, P Zygoura, NJ Latino, JY Douillard, U Dafni, ... ESMO open 5 (5), e000681, 2020 | 8 | 2020 |
Computer-based intensity measurement assists pathologists in scoring phosphatase and tensin homolog immunohistochemistry—clinical associations in NSCLC patients of the … U Rulle, Z Tsourti, R Casanova, KF Deml, E Verbeken, E Thunnissen, ... Journal of Thoracic Oncology 13 (12), 1851-1863, 2018 | 8 | 2018 |
ESMO-Magnitude of Clinical Benefit Scale for haematological malignancies (ESMO-MCBS: H) version 1.0 B Kiesewetter, U Dafni, EGE de Vries, J Barriuso, G Curigliano, ... Annals of Oncology 34 (9), 734-771, 2023 | 7 | 2023 |
Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC—a systematic review and meta-analysis U Dafni, RA Soo, S Peters, Z Tsourti, P Zygoura, K Vervita, JY Han, ... ESMO open 7 (3), 100507, 2022 | 5 | 2022 |
Low neutralizing antibody titers after asymptomatic or non-severe SARS-CoV-2 infection over a 6-month assessment period C Lazor-Blanchet, P Zygoura, U Dafni, F Lamoth, Z Tsourti, MA Lobritz, ... The Journal of Infection 84 (5), 722, 2022 | 4 | 2022 |
European Epidemiology of Pleural Mesothelioma—Real-Life Data From a Joint Analysis of the Mesoscape Database of the European Thoracic Oncology Platform and the European … I Opitz, A Bille, U Dafni, K Nackaerts, L Ampollini, M de Perrot, L Brcic, ... Journal of Thoracic Oncology 18 (9), 1233-1247, 2023 | 1 | 2023 |
A prognostic score for patients with malignant pleural mesothelioma (MPM) receiving second-line immunotherapy or chemotherapy in the ETOP 9–15 PROMISE-meso phase III trial GL Banna, A Addeo, P Zygoura, Z Tsourti, S Popat, A Curioni-Fontecedro, ... Lung Cancer 169, 77-83, 2022 | 1 | 2022 |
PB2707: ESMO-MAGNITUDE OF CLINICAL BENEFIT SCALE FOR HAEMATOLOGICAL MALIGNANCIES (ESMO-MCBS: H) VERSION 1.0 B Kiesewetter, U Dafni, EGE De Vries, J Barriuso, G Curigliano, ... HemaSphere 7 (S3), e02308e3, 2023 | | 2023 |
PD-1-expressing macrophages and CD8 T cells are independent predictors of clinical benefit from PD-1 inhibition in advanced mesothelioma K Homicsko, P Zygoura, M Norkin, S Tissot, N Shakarishvili, S Popat, ... Journal for Immunotherapy of Cancer 11 (10), 2023 | | 2023 |
11P Association of VISTA-expressing CD66b-positive neutrophils, with response and survival benefit from pembrolizumab in advanced malignant pleural mesothelioma K Homicsko, P Zygoura, S Tissot, M Norkin, S Popat, ... Immuno-Oncology and Technology 16, 2022 | | 2022 |